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ABSTRACT
Objectives Real- world data are lacking 
on survival in patients with advanced 
gastroesophageal adenocarcinoma (GOA) 
treated with best supportive care (BSC) alone. 
This knowledge is vital to personalise cancer 
treatment and obtain informed consent. This 
study aimed to define and compare survival in 
patients with advanced GOA treated with and 
without palliative chemotherapy (CTx), and to 
explore the factors that impact prognosis.
Methods Patients in NHS Tayside, Scotland, 
diagnosed with advanced GOA (defined as non- 
resectable) over a 2- year period were identified 
retrospectively. Clinical data were obtained 
from electronic records. Kaplan- Meier and Cox 
regression analysis were performed to determine 
median overall survival (mOS) and investigate 
contributing factors.
Results 127 eligible patients were identified. 
There was a significant difference in mOS 
between patients in the BSC and CTx groups (3.1 
months vs 8.9 months, p=0.00089). This was 
maintained when those deemed not fit for CTx 
were removed. One- year survival was 16% versus 
33%. Cox regression analysis in the BSC 
group identified stage (p<0.001) and Eastern 
Cooperative Oncology Group performance status 
(ECOG PS) (p=0.013) as having independent 
predictive value for survival. Age was not related 
to outcome. Palliative stents were inserted in 48 
patients (37.8%).
Conclusions To our knowledge, this is the 
largest reported study in Europe of outcomes 
in patients with advanced GOA treated with 
BSC only. The mOS with BSC is approximately 
3 months. Cancer stage and ECOG PS have a 
role in prognostication at diagnosis. Our findings 
support the benefit of palliative chemotherapy 
in this population, and real- world survival 
corresponds to published trial data.
INTRODUCTION
The incidence of gastroesophageal adeno-
carcinoma (GOA) has risen steadily in the 
developed world over the last 40 years, 
primarily due to increased prevalence 
of obesity and gastroesophageal reflux 
disease.1 In the UK, there are approxi-
mately 15 000 new cases annually, with 
almost half occurring in patients aged 75 
years and over.2 Sixty to eighty per cent of 
patients present at an advanced stage with 
inoperable or metastatic disease, often 
following a period of reduced oral intake 
and significant symptom burden.3
There are limited treatment options 
in advanced GOA. Chemotherapy is 
the backbone of palliative therapy and 
for those patients fit and able to receive 
systemic therapy, median overall survival 
(mOS) in clinical trials is less than a year.4 
In addition, palliative chemotherapy often 
has a high toxicity burden and impact on 
quality of life (QoL), with over half of 
patients requiring a hospital admission at 
least once during treatment.4 5
It is recognised that there is a mismatch 
in terms of age, fitness and comorbidity 
between real- world patients and those 
recruited to clinical trials on which 
survival and toxicity figures are based. For 
example, the median age in the Random-
ized ECF for Advanced and Locally 
Advanced Esophagogastric Cancer 2 
(REAL-2) trial, which established a stan-
dard of care, was 63 compared with the 
median age of diagnosis of 74 years old 
in the population as a whole.4 We can 
therefore assume that the true impact of 
treatment on patient’s QoL is likely to be 
greater.
This led to the Alternative chemo-
therapy for frail or elderly patients with 
advanced gastric or oesophageal cancer 
(GO2) trial, which investigated reduced 
dose chemotherapy in patients with 
advanced gastro- oesophageal cancer 
in whom there was a doubt over suit-
ability for full- dose therapy. Reduced 
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non- inferior in terms of survival (mOS was 7.6 
months) and was better tolerated.6
Despite a wealth of data on survival outcomes with 
systemic therapy, very little data exist on survival with 
best supportive care (BSC) alone. BSC is defined as 
no further active anticancer treatment with a focus on 
symptom control. This can either be in the community 
or in a hospital/hospice setting. Most of the data that 
exist are historic and based on small patient numbers 
with mOS ranging from 3 to 5 months.7–9 Recent data 
from the BSC arm of the GO2 trial reported an mOS 
of 3.0 months.10 The data, however, do not capture 
those patients who are diagnosed in the community or 
hospital and never meet a cancer specialist.
Given the modest survival benefit provided by chemo-
therapy, to adequately inform patients regarding the 
risks and benefits of treatment and to guide clinicians, 
a better understanding of outcomes with supportive 
care only is required. This study aimed to address this 
problem. We sought to define and compare survival in 
patients with advanced GOA treated with and without 
palliative chemotherapy in our region, and to explore 
the baseline factors that may impact prognosis in those 
who do not receive systemic therapy.
METHODS
This was a retrospective study. Patients in NHS Tayside, 
Scotland, diagnosed with advanced GOA (defined 
as non- resectable) over a 2- year period between 1 
January 2016 and 31 December 2017 were identified 
using multidisciplinary team meeting records. Clinical 
data were then obtained from paper and electronic 
medical records. Those with pathological confirmation 
of oesophageal, gastroesophageal junctional or gastric 
adenocarcinoma were included. For all patients, base-
line demographic data (age, sex, site of primary, stage, 
Eastern Cooperative Oncology Group performance 
status (PS)) were recorded. For those who were not 
seen in an oncology clinic, PS was obtained from the 
available medical records. The date of biopsy was 
taken as the date of diagnosis for all patients.
Survival was defined as date of diagnosis to date 
of death to enable comparison between groups with 
a censor date of 1 January 2020. Patients who either 
chose not to have active treatment with either systemic 
therapy or radiotherapy or were deemed not suitable 
were labelled ‘best supportive care’.
Kaplan- Meier analysis for survival was performed 
to determine mOS using R statistical software version 
4.0.2. Cox regression analysis was used to determine 
contributing baseline factors.
RESULTS
One hundred and fifty- two patients were diagnosed 
with advanced GOA in NHS Tayside during the time 
period. The median age at diagnosis was 73 (range 
36-95) years. Fifty- two (34.2%) of patients received 
palliative chemotherapy and 75 (49.3%) had BSC 
only. Twenty- five (16.4%) patients had palliative 
radiotherapy only and were excluded from the anal-
ysis. Forty- eight (37.8%) patients within the cohort 
required a palliative oesophageal/gastro- oesophageal 
junctional stent for dysphagia.
The patient demographics are shown in table 1. Of 
the 127 patients eligible for analysis, 39 (31%) were 
women and 88 (69%) men. Seventy- four (57%) had a 
PS of 0 or 1, 21% had a PS of 2 and 18% had a PS >2. 
Those who received chemotherapy were significantly 
younger than those who did not (median 68 vs 80 years; 
p<0.019), had more advanced disease (p=0.0004), 
were of better PS (p<0.0001) and had higher base-
line albumin (p=0.034). The most common palliative 
chemotherapy regime used was epirubicin/oxaliplatin/
capecitabine (EOX) (table 1).
There was a significant difference in mOS between 
patients in the BSC and CTx groups (3.1 months vs 






P valuen = 75 n = 52
Age (median, 
years±range)
80 (54–95) 68 (36–83) 0.019
Sex 0.56
  Male 50 (67%) 38 (73%)
  Female 25 (33%) 14 (27%)
ECOG PS <0.0001
  0/1 30 (40%) 44 (85%)
  2 22 (29%) 5 (10%)
  >2 22 (29%) 1 (2%)
  Unknown 1 (1%) 2 (4%)
TNM stage
  Stage 1/2 16 (21%) 0 (0%) 0.0004
  Stage 3 16 (21%) 9 (17%)
  Stage 4a 10 (13%) 6 (12%)
  Stage 4b 29 (39%) 37 (71%)
  Unknown 4 (5%) 0 (0%)
Stent inserted 28 (37%) 20 (38%) 0.72
Albumin (g/dL) 32 (25–36) 37 (32–39) 0.034
Chemotherapy regime
  EOX 28 (54%)
  OX 14 (27%)
  EOF 1 (2%)
  ECX 1 (2%)
  CX 2 (4%)
  CX- H 6 (12%)
The TNM Classification of Malignant Tumours (TNM) is a globally 
recognised standard for classifying the extent of spread of cancer. For 
this study, TNM edition 8 was used.
CX, cisplatin/capecitabine; CX- H, cisplatin/capecitabine/trastuzumab; 
ECOG PS, Eastern Cooperative Oncology Group Performance Status; 
ECX, epirubicin/cisplatin/capecitabine; EOF, epirubicin/oxaliplatin/5- 
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8.9 months, p=0.00089) (figure 1). This was main-
tained when those deemed not fit (defined as PS 
>2) for CTx were removed from the BSC cohort 
(3.9 months vs 8.9 months, p=0.012). One- year 
survival was 16% in the BSC cohort and 33% in those 
who received CTx. Patients who received CTx with 
PS 0, 1 and 2 had mOS of 11.3 versus 8.1 versus 5.8 
months, respectively.
Of the 52 patients who received first line pallia-
tive CTx, 16 (30.8%) went on to receive second line 
systemic therapy and only 3 (5.8%) received subse-
quent line therapy. Seven (13.5%) patients died within 
30 days of their last cycle of CTx and 27 (51.9%) 
within 90 days.
Cox regression analysis in the BSC group identified 
increasing stage and poorer PS as having independent 
predictive value for survival (figure 2). An albumin 
<30 g/dL at diagnosis was also associated with poorer 
survival. Older age or sex was not related to outcome. 
For those receiving CTx, only an albumin <30 g/dL 
was associated with poorer survival.
DISCUSSION
Advanced gastroesophageal adenocarcinoma is an 
increasingly common disease with a very poor prog-
nosis. It is associated with high symptom burden and 
use of healthcare resources demonstrated by the signif-
icant use of out of hours services in the last year of 
life11 and the requirement for stent insertion by over a 
third of patients shown by this study.
Chemotherapy can improve survival but with an 
impact on QoL due to treatment- related side effects 
as well as the need to attend hospital for treatment. 
Despite multiple clinical trials comparing treatment 
regimes, information is lacking as to prognosis without 
chemotherapy. This is essential to adequately guide 
both patients and clinicians in their decision making 
around palliative treatment, particularly in the context 
of recent reports in the UK and the USA highlighting 
that older patients with cancer often value QoL over 
length of life.12 13
In this study, we present real- world data from our 
cohort of patients in Scotland. The median age of diag-
nosis (73 years old) of our population and the male to 
female ratio of approximately 3:1 is in keeping with 
UK and Scottish national figures,2 14 suggesting that 
this is a representative cohort.
We demonstrate that the median survival, in our 
real- world population, with supportive care alone is 
96 days—in keeping with previously published data 
Figure 1 Kaplan- Meier survival analysis for NHS Tayside 
patients with advanced gastroesophageal cancer treated with 
palliative chemotherapy (blue line) or supportive care alone (red 
line). BSC, best supportive care; OS, overall survival.
Figure 2 Cox regressional analysis for factors influencing survival in patients with advanced gastroesophageal adenocarcinoma 
treated with supportive care only. ECOG PS, Eastern Cooperative Oncology Group Performance Status; OS, overall survival; Tumour 
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from randomised trials in smaller cohorts.7–10 We also 
demonstrate that stage of disease, PS and nutritional 
status (using the surrogate marker of albumin) have 
independent prognostic value in the context of BSC.
Age was not related to survival suggesting disease 
biology/stage and patient fitness are the main drivers in 
outcome. This is supported by the fact that almost one 
in five patients survived to 1 year without treatment, 
highlighting the range of disease trajectories. Despite 
this, those in the BSC arm were significantly older than 
those who received chemotherapy, likely reflecting a 
combination of patient choice, and an increased prev-
alence of frailty with age which is known to impact 
clinician confidence in prescribing treatment.
In those eligible for chemotherapy, defined as having 
a PS of ≤2, survival was improved with treatment—
mOS was approximately 8.9 months, an increase of 
5.9 months compared with BSC. This benefit is similar 
to published data.15 The EOX arm of the REAL-2 trial, 
on which our standard of care is based, reported an 
mOS of 11.2 months—this is broadly similar to our 
cohort of patients with PS 0 but is greater than that in 
those with poorer PS.4 This again highlights the differ-
ence between trial and real- world populations and the 
importance of patient selection. It is also important 
to highlight that following progression on treatment, 
prognosis is poor. In our study 52% of patients died 
within 90 days of their last cycle of treatment.
Although QoL and symptom data were missing from 
our analysis, chemotherapy has been shown to improve 
symptom burden with subsequent QoL benefits in the 
palliative setting.7 The requirement of gastroesopha-
geal stent insertion for more than a third of patients 
highlights the importance and demand for this proce-
dure in the palliation of symptoms.
In summary, our data indicate that prognosis in 
advanced GOA is approximately 3 months with 
supportive measures, but in selected patients survival 
can be improved with chemotherapy. Our results 
provide real- world data for clinicians to reference 
when considering and discussing treatment options 
with patients, which will be invaluable for aiding prog-
nostication. This is not only useful for cancer special-
ists but also the patient’s primary care provider as 
we try to minimise harm from treatment toxicity and 
hospital admission. From a patient perspective, knowl-
edge of their likely prognosis is an essential compo-
nent of shared decision making, particularly when the 
burden of treatment is significant.
CONCLUSION
In advanced GOA, mOS with BSC alone is approx-
imately 3 months, however, longer- term survival is 
seen. Treatment with chemotherapy improves survival 
in those who are fit to receive it. Knowledge of the 
benefit chemotherapy brings is an important factor in 
enabling patients to make an informed decision around 
their management.
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